Site search

Clear filter
2811 results for '' found
CAMBRIA-2: Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant [AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader] Versus Standard Endocr
CAMBRIA-2: Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant [AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader] Versus Standard Endocr
/
A multicentre, cluster randomised, double cross over pragmatic clinical trial comparing the safety and efficacy of enteral olanzapine with quetiapine in critically ill patients with hyperactive d
A multicentre, cluster randomised, double cross over pragmatic clinical trial comparing the safety and efficacy of enteral olanzapine with quetiapine in critically ill patients with hyperactive d
/
Multicentre, adaptive, double blind, three arm placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery (NCT05447559)
Multicentre, adaptive, double blind, three arm placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery (NCT05447559)
/
A Phase 1, Open-label, Multicenter Clinical Trial of S095035 (MAT2A Inhibitor) in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP (NCT06188702)
/
Phase I, open label, study of B-cell Maturation Antigen (BCMA)-directed CAR-T cells in adult patients with multiple myeloma (NCT04318327)
Phase I, open label, study of B-cell Maturation Antigen (BCMA)-directed CAR-T cells in adult patients with multiple myeloma (NCT04318327)
/
Catheter Ablation versus Anti-arrhythmic Drugs for Ventricular Tachycardia (CAAD-VT): A Randomised Trial (ACTRN12620000045910)
Catheter Ablation versus Anti-arrhythmic Drugs for Ventricular Tachycardia (CAAD-VT): A Randomised Trial (ACTRN12620000045910)
/
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator’s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor
/
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with R
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with R
/
A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care
A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care
/
A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (NCT03400332)
A Phase 1/2 Study of BMS-986253 in Combination with Nivolumab or Nivolumab plus Ipilimumab in Advanced Cancers (NCT03400332)
/
46 47 48 49 50